Figure 7.

Response of NIH/3T3 cells expressing HER2 fusions to T-DM1 and trastuzumab. A. Response of NIH/3 T3 cells expressing HER2 fusions to T-DM1. Cells were treated with T-DM1 at indicated concentrations for 72 hrs and cell proliferation was measured by MTS assay. The error bars represent SD. B-C. Anti-tumor efficacy of trastuzumab in xenograft models expressing the HER2 fusions. Nude mice bearing NIH/3 T3 xenografts stably expressing the MDK-HER2 (B) or ZNF207-HER2 fusion variant (C), were treated with trastuzumab at 15 mg/kg biweekly and the tumor size was measured with a caliper. The error bars represent SEM and students’ T-tests were used to compare the growth rate in the treatment group with that in the control group *: P < 0.05.